Can the CSL share price regain its 52-week high in 2022?

One broker is optimistic on the outlook for CSL shares.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points
  • After last seeing a 52-week high last year, CSL shares have been stuck in the mud lately
  • The healthcare giant's last all-time high was way back in 2020
  • But one broker is tipping big things for the CSL share price

It's been many moons since we last saw a 52-week high for the CSL Limited (ASX: CSL) share price. Today, shares of the ASX 200 healthcare giant are going for $296.90 each at the time of writing, down by 0.58% over the session so far.

But we have to backtrack to November last year to find the last time this company was hitting new highs. Back in late November, we saw the CSL share price hit a high of $319.78 per share.

That is the company's reigning 52-week high – a level we haven't seen the company even approach since. In fact, it was only three months or so later that CSL was hitting a new 52-week low of $240.10 per share.

So today, CSL shares are close to the middle of this 52-week range.

This begs the question: what's next for the CSL share price? Will we be heading back to the company's 52-week high in 2022?

Two happy scientists analysing test results in a lab

Image source: Getty Images

Is the CSL share price heading back to its 52-week high in 2022?

Well, one ASX broker reckons CSL is in with more than a chance. As my Fool colleague James covered just yesterday, broker Citi is expecting big things from the ASX 200 healthcare share. Citi likes what it sees with CSL's recent acquisition of Vifor Pharma and its development pipeline.

The broker rated CSL a buy, with a 12-month share price target of $340. Not only is that target well above CSL's current 52-week high, but it is also tantalisingly close to the company's all-time high of $342.75 a share.

Indeed, if this price target came to pass, it would mean an upside of more than 14% on the current CSL share price. But since this target is a 12-month one, we can't say the broker is expecting a new high by the end of this year.

Even so, no doubt investors will welcome that news. But we'll have to wait and see if Citi's projections prove accurate, as always.

In the meantime, CSL shareholders can now look forward to receiving the company's final dividend of $1.758 per share which will be paid out next month on 5 October.

At the current CSL share price, this ASX 200 healthcare share has a market capitalisation of around $144 billion, with a dividend yield of 1.04%.

Motley Fool contributor Sebastian Bowen has positions in CSL Ltd. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

A cool white-bearded man holds his hand up signalling you should halt.
Healthcare Shares

ASX 300 cannabis stock Incannex suspended ahead of 'material update'

The Incannex share price is frozen at 14 cents for now.

Read more »

a doctor in a white coat makes a heart shape with his hands and holds it over his chest where his heart is placed.
Healthcare Shares

Guess which ASX All Ords stock is rocketing 27% on a new FDA approval

Rett Syndrome has finally got an approved treatment.

Read more »

Five healthcare workers standing together and smiling.
Healthcare Shares

Buy these excellent ASX 200 healthcare shares: Goldman Sachs

Goldman has spoken very positively about these healthcare shares this week.

Read more »

medical asx share price represented by doctor giving thumbs up
Healthcare Shares

Guess which ASX biotech stock just rocketed 29% on big FDA news

The ASX healthcare share is attracting investor interest following FDA approval for its targeted cancer therapy compound.

Read more »

A doctor in a white coat sits at her computer with finger on mouth thinking about something in her office with medical equipment in the background.
Healthcare Shares

Should I buy CSL shares while they're under $300?

Can investors make a healthy return with this biotech?

Read more »

A man wearing a white coat holds his hands up and mouth open with joy.
Healthcare Shares

Mesoblast share price rockets 23% on FDA news

Mesoblast has received some good news for the US FDA this morning.

Read more »

A young woman wearing a blue blouse with white polkadots holds her phone up with an intrigued and happy look on her face as she reads some news.
Healthcare Shares

Owners of this ASX 200 share are soon going to receive a bigger dividend

Investors in this healthcare company are about to get a healthy cash boost.

Read more »

an older couple look happy as they sit at a laptop computer in their home.
Healthcare Shares

Hoping to collect the latest CSL dividend? Here's how

The next CSL dividend is fast approaching.

Read more »